Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

459.04 +8.07 (+1.79%)
Streaming Delayed Price Updated: 2:22 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
54 55 Next >
Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags
It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners. 
Via Talk Markets
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 5 Years
Via Benzinga
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
A Nasdaq Bull Market Could Begin in April: 3 Top Stocks to Buy Now
The momentum for these stocks should accelerate when a Nasdaq bull market begins. 
Via The Motley Fool
Why Bluebird Bio Shares Are Plunging Today
Via Benzinga
Here's How Much $100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth Today
Via Benzinga
How Is The Market Feeling About Vertex Pharmaceuticals?
Via Benzinga
5 Top Stocks for April
From growth stocks to dividend stocks, there are plenty of buying opportunities this spring. 
Via The Motley Fool
The 10 Best Stocks to Buy in April 2023
Here are 10 stocks to buy now that could unlock explosive gains in your growth-stock portfolio. 
Via The Motley Fool
Here's a New Million-Dollar Reason to Buy CRISPR Therapeutics
Together, the companies could produce a game-changing product. 
Via The Motley Fool
This Top Growth Stock Is Targeting a Multi-Billion-Dollar Market. Here's What It Means for Investors
It wouldn't be the first time the company finds success in a lucrative area. 
Via The Motley Fool
Have $2,000? 2 Exceptional Stocks to Buy In a Bear Market
The current market is challenging investors' fortitude, but patience can pay off. 
Via The Motley Fool
BioMarin Pharmaceutical Stock Shows Rising Relative Strength
BioMarin Pharmaceutical stock had its Relative Strength Rating upgraded to 77 on Thursday, up from 70 a day earlier. 
Via Investor's Business Daily
What Bear Market? These 2 Winning Stocks Are Still Worth Buying.
These two pharma stocks are rock-solid picks in any kind of market. 
Via The Motley Fool
2 Top Stocks to Buy With $1,000 Right Now
These growth-oriented businesses are marking wins even in a challenging environment. 
Via The Motley Fool
2 No-Brainer Stocks to Buy Before the Next Bull Market
These stocks each have superior businesses that can reward investors over the long haul. 
Via The Motley Fool
2 No-Brainer Growth Stocks to Buy and Hold for Years
A long-term investment in these highly profitable businesses could pay off in manifold returns over the next 5 to 10 years. 
Via The Motley Fool
The 3 Best Growth Stocks to Buy in the Biotech Sector
These three biotech growth stocks are brimming with potential and could offer massive upside for patient investors. 
Via InvestorPlace
Better Growth Stock: Vertex Pharmaceuticals vs. AbbVie
These stocks look reasonably priced considering their future prospects. 
Via The Motley Fool
Alkermes Stock Sees Rising Relative Strength Rating
The Relative Strength (RS) Rating for Alkermes stock climbed into a new percentile Tuesday, as it got a lift from 69 to 77. 
Via Investor's Business Daily
3 Small Financial Software Makers Showing Strong Chart Action
Financial software firms Intapp, Vertex, and GuidewIre are headed toward greater profitability and also boast strong chart action. 
Via MarketBeat
Bullish News May Push Vertex Pharmaceuticals Above 52-Week High
A recent announcement by Vertex Pharmaceuticals is confirming a technical signal that could allow the stock to make a new run at its 52-week high 
Via MarketBeat
Exelixis Stock Shows Rising Relative Price Performance; Still Shy Of Key Benchmark
In a welcome move, Exelixis stock saw its Relative Strength Rating improve to 73 on Monday, up from 69 a day earlier. 
Via Investor's Business Daily
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Could CRISPR Therapeutics Become the Next Moderna?
Both companies use cutting-edge technology. 
Via The Motley Fool
Want $1 Million in Retirement? Buy and Hold These 5 Stocks
There's no guarantee that you'll be a millionaire retiree. But these stocks could improve your odds. 
Via The Motley Fool
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it. 
Via InvestorPlace
Nasdaq Bear Market: 2 Growth Stocks to Buy That Keep Bucking the Trend
These red-hot stocks keep climbing despite the bear market. 
Via The Motley Fool
This Is My Highest-Conviction Stock to Own in 2023 and Beyond
This company has already delivered market-beating returns, but it's not too late to get in. 
Via The Motley Fool
Got $3,000? 3 Growth Stocks to Double Up on Right Now
The great prospects for these stocks make them worthy of bigger bets. 
Via The Motley Fool
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
54 55 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.